Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

@article{Adjei2008PhaseIP,
  title={Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.},
  author={Araba A. Adjei and Roger B. Cohen and Wilbur Franklin and Clive Morris and David Wilson and J. Molina and Lorelei J. Hanson and Lia Gore and Laura Quan Man Chow and Stephen Leong and Lara Maloney and Gilad Gordon and Heidi M. Simmons and Allison Marlow and Kevin S Litwiler and Suzy A. Brown and Gregory Poch and Katie Kane and J. S. Haney and S. Gail Eckhardt},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 13},
  pages={2139-46}
}
PURPOSE To assess the tolerability, pharmacokinetics (PKs), and pharmacodynamics (PDs) of the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancer. PATIENTS AND METHODS In part A, patients received escalating doses to determine the maximum-tolerated dose (MTD). In both parts, blood samples were collected to assess PK and PD parameters. In part B, patients were stratified by cancer type (melanoma v other) and randomly assigned to… CONTINUE READING
Highly Influential
This paper has highly influenced 25 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 293 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Clinical aspects of a phase I study of PD 0325901 , a selective oral MEK inhibitor in patients with advanced cancer

  • P LoRusso, S Krishnamurthi, J Rinehart
  • American Association for Cancer Research…
  • 2007

A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901, in patients with advanced cancer

  • P Lorusso, S Krishnamurthi, JR Rinehart
  • J Clin Oncol 2005;23:194S. (suppl,
  • 2005

A phase 2 study of an oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, or pancreatic cancer

  • D Waterhouse, J Rinehart, AA Adjei
  • Proc Am Soc Clin Oncol
  • 2003

Similar Papers

Loading similar papers…